FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213308040> ?p ?o ?g. }

• W3213308040 endingPage "3630" @default.
• W3213308040 startingPage "3630" @default.
• W3213308040 abstract "Abstract Background Current NCCN and ELN guidelines lack supporting evidence in regards to initiation of cytoreductive therapy in essential thrombocythemia (ET) with extreme thrombocytosis (ExT) ≥1500 x 10 9/L (NCCN guidelines: myeloproliferative neoplasms, version 2. 2019, Barbui, Leukemia, 2018).; we sought to determine prevalence and establish phenotype and genotype correlates for ET with ExT and assess its impact on thrombotic and bleeding events, in the context of aspirin therapy or cytoreduction. Methods 1,249 WHO-defined ET patients evaluated over five decades (1967-2021) were retrospectively recruited from the Mayo Clinic. Conventional criteria were used to define major arterial and venous thrombosis and major hemorrhage. Conventional statistical methods were applied using JMP Pro 14.0.0 software package, SAS Institute, Cary, NC. Results i) Phenotype and genotype correlates Among 1,249 consecutive patients with ET, 104 (8%) displayed Ext ≥1500 x 10 9/L, at time of initial diagnosis; these patients were characterized by younger age (median 47 vs 59 years; p&lt;0.001) female gender (80% vs 62%; p&lt;0.001), CALR mutation (39% vs 25%; p=0.004), lower hemoglobin (median 13.1 vs 13.7 g/dl; p&lt;0.0001), leukocytosis ≥11 x 10 9/l (42% vs 23%; p&lt;0.0001), and palpable splenomegaly (22% vs 14%; 0.03); multivariable analysis confirmed associations with age, anemia, leukocytosis, and CALR mutation. Acquired von Willebrand syndrome was reported in 4/9 (44%) vs 27/78 (35%) tested patients, with or without Ext ≥1500 x 10 9/L, respectively (p=0.57); however, comparison using platelet ≥1000 x 10 9/L resulted in near-signficant difference (46% vs 29%; p=0.11). NGS was performed in 297 patients and showed a non-sigificant association with U2AF1 mutations (5% vs 0.4%; p=0.11). ExT ≥1500 x 10 9/L was present in 25/986 (3%), 42/891 (5%), and 15/558 (3%) in the validation cohort; the limited number of cases precluded comparative analyses. ii )Correlation with vascular events at/prior to diagnosis Arterial or venous thrombosis at/prior to diagnosis occurred in 190 (15%) and 111 (9%) patients, respectively, and major hemorrage in 50 (4%). Ext ≥1500 x 10 9/L was associated with major hemorrhage (HR 2.9; 1.3-6.3), but not with arterial (p=0.15) or venous (p=0.41) thrombotic events, at/prior to diagnosis. Instead, multivariable analysis for events at/prior to diagnosis identified male gender (p=0.02), JAK2 mutation (p=0.01), and cardiovascular risk factors (p=0.001) as risk factors for arterial thrombosis and JAK2 mutation (HR 2.8; 1.4-5.7) as a risk factor for venous thrombosis. iii ) Correlation with vascular events after diagnosis At median follow-up of 10 years, arterial or venous thrombosis occurred in 222 (18%) and 97 (8%) patients, respectively, and major hemorrage in 128 (11%). Ext ≥1500 x 10 9/L at diagnosis was not associated with arterial (p=0.35) or venous (p=0.23) thrombosis-free survival or hemorrhage-free survival (p=0.24). Instead, multivariable analysis identified age &gt;60 years, presence of cardiovascular risk factors, and history of arterial thrombosis, as risk factors for arterial thrombosis-free survival; and male gender and history of venous thrombosis as risk factors for venous thrombosis-free survival; and age &gt;60 years and leukocytosis of ≥11 x 10 9/L as risk factors for hemorrhage-free survival. In addition, aspirin therapy was idependently protective of venous thrombosis (HR 0.5; 0.2-0.9), and also of arterial thrombosis, in univariate analysis (HR 0.6; 0.3-0.9), without being associated with an increased risk of major hemorrhage (p=0.64); by contrast, beneficial effect from cytoreductive therapy was not evident for either arterial (p=0.37) or venous (p=0.77) thrombosis. In low-risk patients with Ext ≥1500 x 10 9/L, both aspirin and cytoreductive therapy were protective of venous events (Figure 1), without affecting hemorrhage-free survival. Conclusion ExT ≥1500 x 10 9/L in ET was associated with major hemorrhage at diagnosis but did not affect thrombosis-free or hemorrhage-free survival. Initial therapy with aspirin and/or cytoreductive therapy was protective of venous events in ET patients with ExT ≥1500 x 10 9/L, including those with low-risk disease, without enhancing the risk of hemorrhage. The limited number of informative cases with ExT in the validation cohort, underscore the foreseeable challenges associated with controlled studies. Figure 1 Figure 1. Disclosures Szuber: Novartis: Honoraria. Vannucchi: AbbVie: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees. Barbui: AOP Orphan: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W3213308040 created "2021-11-22" @default.
• W3213308040 creator A5002643270 @default.
• W3213308040 creator A5008437556 @default.
• W3213308040 creator A5008555804 @default.
• W3213308040 creator A5014945673 @default.
• W3213308040 creator A5016216479 @default.
• W3213308040 creator A5024612499 @default.
• W3213308040 creator A5046772202 @default.
• W3213308040 creator A5050506089 @default.
• W3213308040 creator A5052893667 @default.
• W3213308040 creator A5054304877 @default.
• W3213308040 creator A5061275603 @default.
• W3213308040 creator A5069072959 @default.
• W3213308040 creator A5073001728 @default.
• W3213308040 date "2021-11-05" @default.
• W3213308040 modified "2023-09-30" @default.
• W3213308040 title "The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events" @default.
• W3213308040 doi "https://doi.org/10.1182/blood-2021-149223" @default.
• W3213308040 hasPublicationYear "2021" @default.
• W3213308040 type Work @default.
• W3213308040 sameAs 3213308040 @default.
• W3213308040 citedByCount "0" @default.
• W3213308040 crossrefType "journal-article" @default.
• W3213308040 hasAuthorship W3213308040A5002643270 @default.
• W3213308040 hasAuthorship W3213308040A5008437556 @default.
• W3213308040 hasAuthorship W3213308040A5008555804 @default.
• W3213308040 hasAuthorship W3213308040A5014945673 @default.
• W3213308040 hasAuthorship W3213308040A5016216479 @default.
• W3213308040 hasAuthorship W3213308040A5024612499 @default.
• W3213308040 hasAuthorship W3213308040A5046772202 @default.
• W3213308040 hasAuthorship W3213308040A5050506089 @default.
• W3213308040 hasAuthorship W3213308040A5052893667 @default.
• W3213308040 hasAuthorship W3213308040A5054304877 @default.
• W3213308040 hasAuthorship W3213308040A5061275603 @default.
• W3213308040 hasAuthorship W3213308040A5069072959 @default.
• W3213308040 hasAuthorship W3213308040A5073001728 @default.
• W3213308040 hasConcept C126322002 @default.
• W3213308040 hasConcept C151730666 @default.
• W3213308040 hasConcept C2778248108 @default.
• W3213308040 hasConcept C2778923028 @default.
• W3213308040 hasConcept C2779343474 @default.
• W3213308040 hasConcept C2779788118 @default.
• W3213308040 hasConcept C2781057849 @default.
• W3213308040 hasConcept C71924100 @default.
• W3213308040 hasConcept C86803240 @default.
• W3213308040 hasConcept C89560881 @default.
• W3213308040 hasConcept C90924648 @default.
• W3213308040 hasConceptScore W3213308040C126322002 @default.
• W3213308040 hasConceptScore W3213308040C151730666 @default.
• W3213308040 hasConceptScore W3213308040C2778248108 @default.
• W3213308040 hasConceptScore W3213308040C2778923028 @default.
• W3213308040 hasConceptScore W3213308040C2779343474 @default.
• W3213308040 hasConceptScore W3213308040C2779788118 @default.
• W3213308040 hasConceptScore W3213308040C2781057849 @default.
• W3213308040 hasConceptScore W3213308040C71924100 @default.
• W3213308040 hasConceptScore W3213308040C86803240 @default.
• W3213308040 hasConceptScore W3213308040C89560881 @default.
• W3213308040 hasConceptScore W3213308040C90924648 @default.
• W3213308040 hasIssue "Supplement 1" @default.
• W3213308040 hasLocation W32133080401 @default.
• W3213308040 hasOpenAccess W3213308040 @default.
• W3213308040 hasPrimaryLocation W32133080401 @default.
• W3213308040 hasRelatedWork W1990520184 @default.
• W3213308040 hasRelatedWork W1999380519 @default.
• W3213308040 hasRelatedWork W2105496815 @default.
• W3213308040 hasRelatedWork W2157395682 @default.
• W3213308040 hasRelatedWork W2296606610 @default.
• W3213308040 hasRelatedWork W2891888128 @default.
• W3213308040 hasRelatedWork W2981471710 @default.
• W3213308040 hasRelatedWork W3112740757 @default.
• W3213308040 hasRelatedWork W4237599815 @default.
• W3213308040 hasRelatedWork W179981250 @default.
• W3213308040 hasVolume "138" @default.
• W3213308040 isParatext "false" @default.
• W3213308040 isRetracted "false" @default.
• W3213308040 magId "3213308040" @default.
• W3213308040 workType "article" @default.